China channel feed

In clash over sci­ence and na­tion­al se­cu­ri­ty, Chi­nese ri­val to Il­lu­mi­na strug­gles with US ex­pan­sion

Last year
In Focus
Diagnostics

Lian­Bio to shut­ter, end­ing Shang­hai-based start­up’s transat­lantic am­bi­tions

Last year
People
Startups

Seat­tle biotech found­ed by for­mer Seagen lead­ers nabs $112M for three clin­i­cal-stage AD­Cs

Last year
Financing
Startups

Up­dat­ed: ‘Ruth­less’ pipeline pri­or­i­ti­za­tion, obe­si­ty and Chi­na: Three take­aways from As­traZeneca’s Q4 

Last year
Pharma

House com­mit­tee plans hear­ing on Chi­nese biotech com­pe­ti­tion as ten­sions mount

Last year
Pharma

I-Mab Bio­phar­ma to split US, Chi­na busi­ness­es to cut costs, mit­i­gate po­ten­tial risks

Last year
Deals

Ar­riVent out­lines plans for $135M IPO in sec­ond biotech list­ing of 2024

Last year
Financing
Startups

As­traZeneca reshuf­fles Chi­na lead­er­ship, sets up bio­phar­ma group to mir­ror glob­al struc­ture

Last year
People
Pharma

BioN­Tech pays $20M up­front for two mon­o­clon­al an­ti­bod­ies from Chi­na's WuXi Bi­o­log­ics

Last year
Deals

CNS biotech My­robal­an Ther­a­peu­tics rais­es $24M Se­ries A to en­ter the clin­ic

Last year
Financing
Startups

RTW, Bay­er back Cy­to­ki­net­ics-al­lied Ji Xing Phar­ma­ceu­ti­cals with $162M: #JPM24

Last year
Financing
Pharma

GSK to buy asth­ma biotech Aio­los Bio for up to $1.4B three months af­ter start­up emerged: #JPM24

Last year
Deals
Pharma

Bei­jing on­col­o­gy biotech Avi­s­tone rais­es $140M Se­ries B for com­mer­cial­iza­tion in Chi­na, ex­pan­sion in­to US

Last year
Financing

An­oth­er day, an­oth­er ADC: On­Cusp se­cures $100M Se­ries A from No­vo, Or­biMed and oth­ers to run PhI tri­al

Last year
Financing
Startups

Ex­clu­sive: Af­ter Turn­ing Point suc­cess, on­col­o­gy vets in-li­cense first as­set for Aven­zo Ther­a­peu­tics

Last year
Startups
Deals

Trail­ing No­var­tis and Eli Lil­ly, ra­dio­phar­ma­ceu­ti­cals start­up Full-Life Tech­nolo­gies nabs $63M to test new PS­MA drug

Last year
Financing
Manufacturing

Roche inks $50M ADC pact with Chi­nese biotech as field­'s flur­ry spills over in­to 2024

Last year
Deals
Pharma

As­traZeneca makes $1B deal for Gra­cell and its cell ther­a­pies, adding to Chi­na ties

Last year
Deals
Cell/Gene Tx

GSK se­cures an­oth­er ex-Chi­na ADC deal with Han­soh Phar­ma with $185M up­front

Last year
Deals

Ab­bisko signs $70M up­front deal with Mer­ck KGaA for PhI­II can­cer drug

Last year
Deals

Small transpa­cif­ic team led by Lil­ly, Ever­est vet turns to com­pu­ta­tion­al tools for next wave of pep­tide drug dis­cov­ery

Last year
Financing
Startups

BioN­Tech grabs PD-L1/VEGF bis­pe­cif­ic with $55M up­front, ex­pand­ing pipeline while low­er­ing Covid guid­ance

Last year
Deals

FDA green­lights first made-in-Chi­na PD-1 as Jun­shi, Co­herus beat BeiGene to the punch

Last year
FDA+

Dana­her’s third-quar­ter rev­enue from biotech ser­vices down 19% amid slow­down in Chi­na, US

Last year
Outsourcing
Pharma
First page Previous page 6789101112 Next page Last page
A service from the Financial Times